Q-omics provides the consensus-scored FAM138C profile across patient tissues and cancer cell-line models. FAM138C expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM138C is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, FAM138C RNA expression shows 4,831 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, LUSC, and STAD as cancer lineages where FAM138C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM138C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM138C survival associations across molecular data types. FAM138C RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM138C RNA expression–survival associations across cancer types. High FAM138C expression shows unfavorable associations in COAD, ACC, LUSC, KIRC and CHOL, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM138C RNA expression.
This table summarizes FAM138C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM138C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM138C shows lower tumor expression in LUSC, UCEC and LUAD. The LUSC box plot shows higher FAM138C RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .001).
This table shows molecular features associated with FAM138C in patient tissues and cancer cell lines. In patient samples, FAM138C shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
